ESMO: AstraZeneca-Daiichi get clarity on patient deaths for Enhertu follow up Dato-DXd, survival data still unclear

Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd.

The gist of the safety update, presented in a late-breaking session at the European Society for Medical Oncology Congress in Madrid on Monday afternoon, is that more patients in the lung cancer study experienced interstitial lung disease (ILD) when taking datopotamab deruxtecan (Dato-DXd), compared to breast cancer.